Attovia Therapeutics

ATTO

Capitalización de mercado USD 627 M

SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026.

Attovia Therapeutics, Inc. (ATTO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

August's seven U.S. IPOs matched the prior month's deal count, while aggregate proceeds declined modestly. The month saw $1.8 billion in total proceeds compared to the $3.0 billion raised in July and the $2.9 billion raised across seven IPOs in August 2025. Issuance was dominated by the healthcare sector, which priced five deals and accounted for over $1.4 billion of the total proceeds raised.

SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming investor conferences:

ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026

Attovia Therapeutics (NASDAQ:ATTO) has arrived on public markets with a pipeline built entirely on one bet: that a biparatopic antibody platform called Attobody can turn well-validated immunology targets into next-generation biologics.

Six IPOs and five SPACs priced this week. Two IPOs and eight SPACs submitted filings. One sizable US IPO is currently scheduled for the week ahead, along with a notable closed-end fund.